Medically reviewed by Maggie Ford, FNP, Aqua Vitae Greenville
If you are navigating midlife weight gain or perimenopause, you have likely heard two major health conversations happening at once. The first is the rise of GLP-1 receptor agonists, like semaglutide and tirzepatide, for weight loss. The second is the return of bioidentical hormone replacement therapy (BHRT) for hormone balance and symptom relief.
As both treatments grow in popularity, patients and providers are asking an important question about GLP-1s and BHRT. Do they work together to improve health, or do they cancel each other out? Early research is encouraging. When used together under medical supervision, hormone therapy may boost the weight loss, metabolic benefits, and overall vitality that GLP-1 medications offer. This article looks at what current science says about pairing the two.
What the Research Says About Combining GLP-1s and Hormone Therapy
For years, women entering perimenopause and menopause have noticed a frustrating change. Weight gain, especially around the belly, becomes harder to shift with diet and exercise alone. Declining estrogen affects insulin sensitivity and changes how the body stores fat. Recent studies suggest that addressing hormones alongside metabolic health may make a real difference.
Greater Weight Loss With Semaglutide and Hormone Therapy
A Mayo Clinic study reviewed records of 106 postmenopausal women taking semaglutide for weight management. At 12 months, women taking both semaglutide and hormone therapy lost an average of 16% of their body weight. Women taking semaglutide alone lost an average of 12%.
A Similar Trend With Tirzepatide
A later Mayo Clinic study on tirzepatide found a similar pattern in 120 postmenopausal women. Those on hormone therapy lost an average of 19.2% of their body weight, compared with 14% for those taking tirzepatide alone. A larger share of the hormone therapy group also reached 20% or more total weight loss.
Both studies were retrospective, meaning researchers reviewed past medical records rather than assigning treatments. Because of that, they cannot prove that hormone therapy caused the extra weight loss. Still, the results point in the same direction.
Why Estrogen May Help GLP-1s Work
Why might hormone therapy boost GLP-1 results? Lab and animal research offers some clues. Estrogen appears to stimulate natural GLP-1 release from gut cells. In animal studies, estrogen also seems to strengthen GLP-1 signals in the brain areas that control appetite and food reward.
When estrogen drops during midlife, the body may respond less strongly to fullness signals. Researchers think restoring estrogen could help the body respond better to GLP-1 medications. In turn, that may make it easier to quiet “food noise” and cravings. More research in women is needed to confirm this.
“Many of the women we see on a GLP-1 are also dealing with hot flashes, poor sleep, and changes in muscle and bone that the medication alone does not address. The Mayo Clinic research on semaglutide and hormone therapy suggests these treatments may support each other. That is why we look at hormone and metabolic health together before building a plan.”
Maggie Ford, FNP, Aqua Vitae Greenville
How GLP-1s and BHRT Complement Each Other
Rather than working against each other, GLP-1s and BHRT target different but connected systems in the body. Seeing them side by side makes it easier to understand why they may pair well. Here is how they compare, along with two areas where the combination may matter most.
GLP-1s and BHRT Side by Side
| Health Goal | GLP-1 Medications (Semaglutide, Tirzepatide) | BHRT (Estradiol, Progesterone, DHEA) |
|---|---|---|
| Primary target | Appetite centers in the brain, stomach emptying, and blood sugar control | Hormone receptors throughout the brain, bones, and other tissues |
| Metabolic impact | Lowers calorie intake and fasting glucose and reduces body fat | May improve insulin sensitivity and limit belly fat gain |
| Symptoms addressed | Obesity, metabolic syndrome, and prediabetes | Hot flashes, night sweats, brain fog, mood swings, and vaginal dryness |
| Muscle and bone | Promotes fat loss but takes effort to protect muscle | Supports muscle maintenance and bone density |
Protecting Lean Muscle and Bone Density
Fast weight loss on a GLP-1 carries a known risk. In clinical trials, the weight people lost included some lean muscle along with fat. In the main semaglutide trial, lean mass fell nearly 10 percent over the course of treatment. Estrogen, testosterone, and DHEA all help maintain muscle and bone.
Testosterone often gets left out of menopause care, yet in a 24-week trial of women with low levels, testosterone increased lean body mass at the highest dose tested. Bringing these hormones back into a healthy range with BHRT may help you protect muscle while losing fat. That, in turn, helps preserve your metabolic rate. No study has yet tested testosterone and GLP-1s together, so we pair hormone care with strength training and enough protein, and our lab panels check testosterone along with estrogen and progesterone.
Covering More of Your Symptoms
GLP-1s are powerful tools for weight loss and blood sugar control. However, they do not fix sleep problems, joint stiffness, or hot flashes. BHRT helps address these symptoms at their source. Better sleep and mood also make it much easier to stick with exercise, nutrition goals, and strength training.
Re-evaluating BHRT Safety: Why Hormone Therapy Is Not as “Scary” as It Used to Be
For decades, fear around hormone therapy came from early readings of the 2002 Women’s Health Initiative (WHI) study. Those early interpretations led many women and doctors to overestimate the risks of breast cancer and heart disease. Since then, medical understanding and federal guidance have shifted significantly.
What Has Changed
Today, three key developments are reshaping the conversation:
- The FDA removed major boxed warnings. In late 2025, the FDA began removing boxed warning language about heart disease, breast cancer, and probable dementia from FDA-approved menopausal hormone products. The agency recognized that the original WHI warnings overstated these risks for many women. In early 2026, it approved the first labeling changes. The boxed warning about endometrial cancer remains for estrogen-alone products.
- Bioidentical options are widely available. Bioidentical hormones have the same chemical structure as the hormones your body makes naturally. Options such as transdermal estradiol and micronized progesterone are often plant-derived and are commonly preferred for their natural fit with the body.
- Timing matters. FDA labeling recommends starting systemic hormone therapy within 10 years of menopause or before age 60. For many women in this window, the benefits of treatment may outweigh the risks.
Weighing Your Personal Risks and Benefits
Untreated hormone decline can have long-term effects, including faster bone loss and a higher fracture risk. At the same time, hormone therapy carries risks that vary from person to person. Your provider can help you weigh both sides based on your age, health history, and goals.
Clinical Considerations: Getting the Best Results
People often ask whether GLP-1s work better as a pill or an injection, and the same question comes up with hormones. Each form has its own pros and cons, but how the two therapies interact matters, too. Here are two practical points for safety and results.
Why the Delivery Route Matters
GLP-1 medications work in part by slowing how quickly food leaves your stomach. This slower digestion can make the absorption of oral medications less predictable, including oral progesterone or estradiol tablets. Non-oral routes avoid this issue:
- Transdermal: Patches, gels, or creams absorb through the skin directly into the bloodstream.
- Subcutaneous hormone pellets: Pellets placed under the skin release bioidentical estradiol or testosterone steadily over 3 to 6 months. Because they bypass the digestive system and liver, slower digestion from a GLP-1 does not affect them.
- Sublingual or troches: These dissolve under the tongue or in the cheek and absorb through the lining of the mouth.
Using Each Therapy for the Right Reason
BHRT should not be prescribed solely as a weight-loss booster. Hormone therapy is meant to treat hormone deficiencies and midlife symptoms. A provider should prescribe each medication based on your health history and clinical need.
Ready to Optimize Your Health Journey?
Managing weight loss and hormone health does not have to be guesswork. Because every body is different, safe and effective treatment starts with a personal evaluation. Here is how to take the next step.
Start With Your Labs
At Aqua Vitae, comprehensive lab panels help our providers understand your hormone and metabolic baseline. From there, we can discuss options such as GLP-1 weight-loss management and bioidentical hormone replacement therapy, along with what the latest menopause guidelines mean for you.
Book Your Consultation
Book a consultation with our team to order comprehensive labs, review your hormone and metabolic health, and build a treatment plan designed for your body and long-term goals.
Disclaimer: Always consult a qualified healthcare provider before starting or combining prescription therapies like GLP-1s and BHRT.
Clinical Sources
- Hurtado MD, Tama E, Fansa S, et al. (2024). Weight Loss Response to Semaglutide in Postmenopausal Women With and Without Hormone Therapy Use. Menopause, 31(4), 266-274. DOI: 10.1097/GME.0000000000002310.
- Castaneda R, et al. (2026). The Role of Menopause Hormone Therapy in Modulating Tirzepatide-Associated Weight Loss in Postmenopausal Women With Overweight or Obesity: A Retrospective Cohort Study. The Lancet Obstetrics, Gynaecology, & Women’s Health, 2(2), e118. DOI: 10.1016/S3050-5038(25)00145-1
- Handgraaf S, Dusaulcy R, Visentin F, Philippe J, Gosmain Y. (2018). 17-β Estradiol Regulates Proglucagon-Derived Peptide Secretion in Mouse and Human α- and L Cells. JCI Insight, 3(7), e98569. DOI: 10.1172/jci.insight.98569
- Richard JE, Anderberg RH, López-Ferreras L, Olandersson K, Skibicka KP. (2016). Sex and Estrogens Alter the Action of Glucagon-Like Peptide-1 on Reward. Biology of Sex Differences, 7, 6. DOI: 10.1186/s13293-016-0059-9.
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults With Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. DOI: 10.1056/NEJMoa2032183.
- U.S. Department of Health and Human Services. (2025, November 10). Fact Sheet: FDA Initiates Removal of “Black Box” Warnings From Menopausal Hormone Replacement Therapy Products. hhs.gov
- U.S. Food and Drug Administration. (2026, February 12). FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. fda.gov
- Wilding JPH, et al. (2021). Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 5(Suppl 1). https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
- Huang G, Basaria S, Travison TG, et al. (2014). Testosterone Dose-Response Relationships in Hysterectomized Women With or Without Oophorectomy. Menopause, 21(6), 612–623. PMID: 24281237. https://pmc.ncbi.nlm.nih.gov/articles/PMC4701202/
